Researchers ID Signature for Predicting Lymphoma Treatment Success

Using mutation and gene expression patterns from non-Hodgkin's lymphoma cell lines, scientists from Genentech and elsewhere have come up with a gene expression signature for predicting response to a CD40 stimulating therapy called dacetuzumab that's being developed to treat B cell cancers.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.